5-fluorouracil-interferon-α2b adjuvant treatment of Dukes C colorectal cancer.

Autor: Frasci, Giuseppe, Leone, Francesco, Monaco, Mario, Cremone, Luigi, Sapio, Ugo, Faiella, Felice, Espinosa, Angelo, Persico, Giovanni
Zdroj: Diseases of the Colon & Rectum; Jul1994, Vol. 37 Issue 7, p643-650, 8p
Abstrakt: To determine whether interferon-α2b can improve results of 5-fluorouracil adjuvant treatment of Dukes C colorectal cancer patients, we compared the outcome of patients receiving a fluorouracil-interferon combination to that of historic controls treated with fluorouracil alone.Fifty-seven Dukes C colorectal cancer patients were given 5-fluorouracil-interferon-α in2b adjuvant treatment from October 1986 to September 1990. The results were compared with those obtained in 51 consecutive patients treated at the same institutions with 5-fluorouracil (5-FU) alone (used at the same doses and schedule) between 1983 and 1986. The main prognostic variables were similar in the two groups.No life-threatening toxicity occurred in either group. The addition of interferon (IFN) slighlty impaired tolerance to the treatment; however, the dose of IFN had to be reduced only in five patients and discontinued in one patient. Grade 3 and 4 myelotoxicity was rare and not substantially different in the two groups. Interferon-related side effects (fever, flu-like syndrome, malaise, etc.) were frequent, but, in general, mild or moderate. At the time of this analysis (July 1992), median followup was 49 (range, 20-70) months in the group of patients treated with 5-FU + IFN, and 86 (range, 68-103) months in the group receiving 5-FU alone. There were 17 recurrences and 15 cancer-related deaths among patients receiving combined treatment, and 27 deaths in the group treated with 5-FU alone. Both five-year relapse-free survival (65 percent vs. 47 percent; P=0.043) and causespecific survival (64 percent vs. 46 percent; P=0.038) were significantly better in the patients receiving combined treatment. After correction for the influence of prognostic pretreatment variables, 5-FU + IFN again afforded a significant advantage in terms of both relapse-free (P<0.01) and overall survival (P<0.001).5-FU-IFN-α2b treatment seems to improve the prognosis in Dukes C colorectal cancer patients. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: